TransCode Therapeutics Advances TTX-MC138 to Phase 2a Trials After Positive Phase 1a Results in Metastatic Disease

Reuters10-14

TransCode <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Advances TTX-MC138 to Phase 2a Trials After Positive Phase 1a Results in Metastatic Disease

TransCode Therapeutics Inc. has announced the completion of its Phase 1a clinical trial evaluating TTX-MC138, an investigational inhibitor of microRNA-10b, in patients with metastatic disease. The trial met its primary safety endpoint and established a recommended Phase 2 dose. Sixteen patients were treated across four escalating dose levels, with no significant treatment-related safety events or dose-limiting toxicities observed. The median treatment duration was four months, ranging from two to twelve months, and three patients remain on trial. Preliminary data showed apparent stable disease lasting over four months in 44% of patients. Ongoing data analysis and monitoring are planned, with a final clinical study report, scientific presentations, and publications to be presented in the future. The company plans to advance TTX-MC138 into a Phase 2a clinical trial to further assess efficacy across selected metastatic diseases.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transcode Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE96934) on October 14, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2575777297?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-14 20:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2575777297","market":"nz","top_or_hot":-1,"title":"TransCode Therapeutics Advances TTX-MC138 to Phase 2a Trials After Positive Phase 1a Results in Metastatic Disease","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      TransCode <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Advances TTX-MC138 to Phase 2a Trials After Positive Phase 1a Results in Metastatic Disease\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        TransCode Therapeutics Inc. has announced the completion of its Phase 1a clinical trial evaluating TTX-MC138, an investigational inhibitor of microRNA-10b, in patients with metastatic disease. The trial met its primary safety endpoint and established a recommended Phase 2 dose. Sixteen patients were treated across four escalating dose levels, with no significant treatment-related safety events or dose-limiting toxicities observed. The median treatment duration was four months, ranging from two to twelve months, and three patients remain on trial. Preliminary data showed apparent stable disease lasting over four months in 44% of patients. Ongoing data analysis and monitoring are planned, with a final clinical study report, scientific presentations, and publications to be presented in the future. The company plans to advance TTX-MC138 into a Phase 2a clinical trial to further assess efficacy across selected metastatic diseases.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transcode Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE96934) on October 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TransCode Therapeutics Advances TTX-MC138 to Phase 2a Trials After Positive Phase 1a Results in Metastatic Disease</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTransCode Therapeutics Advances TTX-MC138 to Phase 2a Trials After Positive Phase 1a Results in Metastatic Disease\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-14 20:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      TransCode <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Advances TTX-MC138 to Phase 2a Trials After Positive Phase 1a Results in Metastatic Disease\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        TransCode Therapeutics Inc. has announced the completion of its Phase 1a clinical trial evaluating TTX-MC138, an investigational inhibitor of microRNA-10b, in patients with metastatic disease. The trial met its primary safety endpoint and established a recommended Phase 2 dose. Sixteen patients were treated across four escalating dose levels, with no significant treatment-related safety events or dose-limiting toxicities observed. The median treatment duration was four months, ranging from two to twelve months, and three patients remain on trial. Preliminary data showed apparent stable disease lasting over four months in 44% of patients. Ongoing data analysis and monitoring are planned, with a final clinical study report, scientific presentations, and publications to be presented in the future. The company plans to advance TTX-MC138 into a Phase 2a clinical trial to further assess efficacy across selected metastatic diseases.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transcode Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE96934) on October 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RNAZ","symbol_name":"TransCode Therapeutics  Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251014:nNDL7J5rzz:1","article_id":"2575777297","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2575777297","pubTimestamp":1760443609,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"TransCode Therapeutics Inc. has announced the completion of its Phase 1a clinical trial evaluating TTX-MC138, an investigational inhibitor of microRNA-10b, in patients with metastatic disease. The trial met its primary safety endpoint and established a recommended Phase 2 dose. Sixteen patients were treated across four escalating dose levels, with no significant treatment-related safety events or dose-limiting toxicities observed. The median treatment duration was four months, ranging from two to twelve months, and three patients remain on trial. Preliminary data showed apparent stable disease lasting over four months in 44% of patients. Ongoing data analysis and monitoring are planned, with a final clinical study report, scientific presentations, and publications to be presented in the future. The company plans to advance TTX-MC138 into a Phase 2a clinical trial to further assess efficacy across selected metastatic diseases.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RNAZ":"TransCode Therapeutics  Inc.","BK4139":"生物科技","BK4539":"次新股"},"translate_title":"TransCode Therapeutics将TTX-MC138推进至2a期试验，此前1a期结果呈阳性，导致转移性疾病","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RNAZ":0.9},"content_text":"TransCode Therapeutics Advances TTX-MC138 to Phase 2a Trials After Positive Phase 1a Results in Metastatic Disease\n    \n\n        TransCode Therapeutics Inc. has announced the completion of its Phase 1a clinical trial evaluating TTX-MC138, an investigational inhibitor of microRNA-10b, in patients with metastatic disease. The trial met its primary safety endpoint and established a recommended Phase 2 dose. Sixteen patients were treated across four escalating dose levels, with no significant treatment-related safety events or dose-limiting toxicities observed. The median treatment duration was four months, ranging from two to twelve months, and three patients remain on trial. Preliminary data showed apparent stable disease lasting over four months in 44% of patients. Ongoing data analysis and monitoring are planned, with a final clinical study report, scientific presentations, and publications to be presented in the future. The company plans to advance TTX-MC138 into a Phase 2a clinical trial to further assess efficacy across selected metastatic diseases.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transcode Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE96934) on October 14, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2575777297","isCrawlerRequest":true}